{"symbol":"REGN","fiscalQuarter":"Q4-2012","reportDate":"2013-02-14","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2012","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.64%","keyNumbers":[{"metric":"EPS","actual":"$1.47","expected":"N/A","surprise":"+37.38%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on innovation and expanding our product pipeline."],"summary":"Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters."},"guidanceChanges":{"summary":"No forward guidance was provided in this earnings report.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates effective cost management and profitability, despite the lack of revenue data. The stock's slight decline of 0.64% may reflect investor caution due to the absence of guidance. Overall, the company appears to be on a solid footing but will need to provide more clarity in future reports to reassure investors.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2012 earnings: EPS beat by 37.38%. Stock down 0.64%. Full breakdown."}}